Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.

Pavlides, Michael; Mózes, Ferenc E; Akhtar, Salma; Wonders, Kristy; Cobbold, Jeremy; Tunnicliffe, Elizabeth M; Allison, Michael; Godfrey, Edmund M; Aithal, Guruprasad P; Francis, Susan; Romero-Gomez, Manuel; Castell, Javier; Fernandez-Lizaranzu, Isabel; Aller, Rocio; González, Rebeca Sigüenza; Agustin, Salvador; Pericàs, Juan M; Boursier, Jerome; Aube, Christophe; Ratziu, Vlad; ... (2023). Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol. Contemporary clinical trials, 134(107352), p. 107352. Elsevier 10.1016/j.cct.2023.107352

Text 1-s2.0-S1551714423002756-main.pdf - Accepted Version Restricted to registered users only until 4 October 2024. Available under License Publisher holds Copyright. Download (1MB) | Request a copy

Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small proportion of those with NAFLD will develop progressive liver disease, for which there is currently no approved pharmacotherapy. Identifying those who are at risk of progressive NAFLD currently requires a liver biopsy which is problematic. Firstly, liver biopsy is invasive and therefore not appropriate for use in a condition like NAFLD that affects a large proportion of the population. Secondly, biopsy is limited by sampling and observer dependent variability which can lead to misclassification of disease severity. Non-invasive biomarkers are therefore needed to replace liver biopsy in the assessment of NAFLD. Our study addresses this unmet need. The LITMUS Imaging Study is a prospectively recruited multi-centre cohort study evaluating magnetic resonance imaging and elastography, and ultrasound elastography against liver histology as the reference standard. Imaging biomarkers and biopsy are acquired within a 100-day window. The study employs standardised processes for imaging data collection and analysis as well as a real time central monitoring and quality control process for all the data submitted for analysis. It is anticipated that the high-quality data generated from this study will underpin changes in clinical practice for the benefit of people with NAFLD. Study Registration: clinicaltrials.gov: NCT05479721.

Interest & Impact

Downloads

0 since deposited on 09 Oct 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item